石药集团：与 CORBUS PHARMACEUTICALS 就 SYS6002 订立独家授权协议

Zhitong
2023.02.12 23:18
石药集团港交所公告称，已与 Corbus Pharmaceuticals 就本集团重组人源化抗 Nectin-4 抗体药物偶联物 SYS6002 在美国、欧盟国家、英国、加拿大、澳大利亚、冰岛、列支敦士登、挪威及瑞士的开发及商业化订立独家授权协议。
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.